Clinical Trial Update: A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 prospective study evaluating apatinib in combination with concurrent neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN